Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND.

Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

2.

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.

Schilling S, Rahfeld JU, Lues I, Lemere CA.

Molecules. 2018 May 3;23(5). pii: E1068. doi: 10.3390/molecules23051068. Review.

3.

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.

Hartlage-Rübsamen M, Bluhm A, Piechotta A, Linnert M, Rahfeld JU, Demuth HU, Lues I, Kuhn PH, Lichtenthaler SF, Roßner S, Höfling C.

Molecules. 2018 Apr 17;23(4). pii: E924. doi: 10.3390/molecules23040924.

4.

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.

Piechotta A, Parthier C, Kleinschmidt M, Gnoth K, Pillot T, Lues I, Demuth HU, Schilling S, Rahfeld JU, Stubbs MT.

J Biol Chem. 2017 Jul 28;292(30):12713-12724. doi: 10.1074/jbc.M117.777839. Epub 2017 Jun 16.

5.

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.

Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE.

Alzheimers Res Ther. 2017 Jun 6;9(1):38. doi: 10.1186/s13195-017-0266-6.

6.

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.

Hoffmann T, Meyer A, Heiser U, Kurat S, Böhme L, Kleinschmidt M, Bühring KU, Hutter-Paier B, Farcher M, Demuth HU, Lues I, Schilling S.

J Pharmacol Exp Ther. 2017 Jul;362(1):119-130. doi: 10.1124/jpet.117.240614. Epub 2017 Apr 26.

PMID:
28446518
7.

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Frost JL, Liu B, Rahfeld JU, Kleinschmidt M, O'Nuallain B, Le KX, Lues I, Caldarone BJ, Schilling S, Demuth HU, Lemere CA.

Neurobiol Aging. 2015 Dec;36(12):3187-3199. doi: 10.1016/j.neurobiolaging.2015.08.021. Epub 2015 Aug 31.

8.

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.

Lues I, Weber F, Meyer A, Bühring U, Hoffmann T, Kühn-Wache K, Manhart S, Heiser U, Pokorny R, Chiesa J, Glund K.

Alzheimers Dement (N Y). 2015 Oct 3;1(3):182-195. doi: 10.1016/j.trci.2015.08.002. eCollection 2015 Nov.

9.

Three thiadiazinone derivatives, EMD 60417, EMD 66430, and EMD 66398, with class III antiarrhythmic activity but different electrophysiologic profiles.

Himmel HM, Wettwer E, Lues I, Beier N, Jonas R, Ravens U.

J Cardiovasc Pharmacol. 2001 Sep;38(3):438-49.

PMID:
11486248
10.

Stereoselectivity of actions of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264.

Ravens U, Flüss OM, Li Q, Himmel HM, Wettwer E, Klockow M, Lues I.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):733-42.

PMID:
9205958
11.

In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization.

Haeusler G, Jonas R, Minck KO, Schliep HJ, Schelling P, Weygandt H, Lues I.

J Cardiovasc Pharmacol. 1997 May;29(5):647-55.

PMID:
9213208
12.

EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.

Uhlmann R, Schwinger RH, Lues I, Erdmann E.

Basic Res Cardiol. 1995 Sep-Oct;90(5):365-71.

PMID:
8585857
13.

Involvement of ATP-sensitive potassium channels in preconditioning protection.

Rohmann S, Weygandt H, Schelling P, Kie Soei L, Verdouw PD, Lues I.

Basic Res Cardiol. 1994 Nov-Dec;89(6):563-76.

PMID:
7702545
14.

Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart.

Nankervis R, Lues I, Brown L.

J Cardiovasc Pharmacol. 1994 Oct;24(4):612-7.

PMID:
7528844
15.

Therapeutic potential of potassium channel activators in coronary heart disease.

Haeusler G, Lues I.

Eur Heart J. 1994 Aug;15 Suppl C:82-8. Review.

PMID:
7995277
16.

Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine.

Rohmann S, Weygandt H, Schelling P, Soei LK, Becker KH, Verdouw PD, Lues I, Häusler G.

Cardiovasc Res. 1994 Jun;28(6):858-63.

PMID:
7923292
17.
18.

Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400.

Barber A, Bartoszyk GD, Greiner HE, Mauler F, Murray RD, Seyfried CA, Simon M, Gottschlich R, Harting J, Lues I.

Br J Pharmacol. 1994 Mar;111(3):843-51.

19.
20.

A new cardiotonic drug reduces the energy cost of active tension in cardiac muscle.

Gross T, Lues I, Daut J.

J Mol Cell Cardiol. 1993 Mar;25(3):239-44.

PMID:
8510167
21.

Pharmacological basis for antihypertensive therapy with a novel dopamine agonist.

Haeusler G, Lues I, Minck KO, Schelling P, Seyfried CA.

Eur Heart J. 1992 Sep;13 Suppl D:129-35. Review.

PMID:
1356783
22.

Novel diazinone derivatives separate myofilament Ca2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium.

Ventura C, Miller R, Wolf HP, Beier N, Jonas R, Klockow M, Lues I, Hano O, Spurgeon HA, Lakatta EG, et al.

Circ Res. 1992 Jun;70(6):1081-90.

PMID:
1533576
23.

3-Methyl-2H-1-benzopyran potassium channel activators.

Gericke R, Harting J, Lues I, Schittenhelm C.

J Med Chem. 1991 Oct;34(10):3074-85.

PMID:
1920358
24.

The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".

Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G.

J Cardiovasc Pharmacol. 1991 Jul;18(1):17-27.

PMID:
1719287
25.

Characterization of a novel K+ channel activator, EMD 52962, in electrophysiological and pharmacological experiments.

De Peyer JE, Lues I, Gericke R, Häusler G.

Pflugers Arch. 1989;414 Suppl 1:S191. No abstract available.

PMID:
2780258
26.
27.

Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat.

Gross G, Lues I.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Jun;329(4):427-39.

PMID:
4033808
28.

Effect of removing the endothelial cells on the reactivity of rat aortic segments to different alpha-adrenoceptor agonists.

Lues I, Schümann HJ.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):160-3.

PMID:
6152014
29.

Facilitating interaction between rauwolscine and angiotensin in the mesenteric artery of the rabbit.

Lues I, Vinke R, Schümann HJ.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(3):273-7.

PMID:
6147766
30.

B-HT 920 acts as an alpha 1-adrenoceptor agonist in the rabbit aorta under certain in vitro conditions.

Lues I, Schümann HJ.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Jan;325(1):42-6.

PMID:
6143265
31.

Postjunctional alpha-adrenoceptors in the isolated saphenous vein of the rabbit. Characterization and influence of angiotensin.

Schümann HJ, Lues I.

Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):328-34.

PMID:
6138712
32.

Influence of hypo- and hyperthyroidism on plasma catecholamines in pithed rats.

Nagel-Hiemke M, Gross G, Lues I, Schümann HJ.

Naunyn Schmiedebergs Arch Pharmacol. 1981 Sep;317(2):159-64. No abstract available.

PMID:
7300918

Supplemental Content

Support Center